Grant opportunity · PAR-25-026
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Who can apply (as listed)
- Native American tribal governments (federally recognized)
- Public and state-controlled institutions of higher education
- Independent school districts
- State governments
- Special district governments
- Native American tribal organizations (other than federally recognized governments)
- County governments
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- Private institutions of higher education
- City or township governments
- Public housing authorities / Indian housing authorities
- For-profit organizations (other than small businesses)
- Others (see the opportunity text)
- Small businesses
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.
GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.